Adv Ther April 2022 PMID 34786648

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia.

Valeria Santini, Michael Lübbert, Agnieszka Wierzbowska, Gert J Ossenkoppele

Full text PDF Download social card

Mentions

Peak: 4 in Feb 2022

across 2 sources since Nov 2021

Extended reach

16,085

potential audience

Total likes

Video views

210

Mentions per month

Nov 2021 – Jul 2023

Where it's discussed

X / Twitter11 posts
YouTube1 videos

AI synopsis

What people are saying

Overall, this collection reflects a positive and motivated reception, with users supporting the article’s clinical significance, demonstrated by phrases like 'new article' and 'discusses the clinical value,' as well as sharing related multimedia resources, which indicate active engagement and recognition of the research's impact on treatment approaches.

AgreementModerate agreement

Most social discussions seem to acknowledge the positive findings of the publication, emphasizing the clinical usefulness of decitabine for AML patients, especially the elderly.

InterestHigh interest

Participants exhibit high interest, sharing articles, responding enthusiastically, and referencing specific terms like 'clinical value' and 'advances in therapy', indicating curiosity about treatment options.

EngagementModerate engagement

While some comments are brief, there are multiple references to additional resources like video abstracts and graphical summaries, showing a level of engagement that goes beyond superficial reactions.

ImpactModerate impact

The discussions highlight potential impacts on treatment strategies and patient outcomes, suggesting the publication influences current dialogues on AML management.

Abstract in brief

Decitabine is a hypomethylating agent used to treat adult patients with AML who are not fit for standard chemotherapy, helping to reactivate tumor suppressor genes by inhibiting DNA methyltransferases.
Clinical trials, including phase 3 and phase 2 studies, showed that decitabine significantly improves survival rates and response in AML patients, and it is generally well tolerated across different age groups.
While decitabine works regardless of adverse-risk features like poor karyotypes or TP53 mutations, emerging research suggests it may also be effective in specific AML subtypes, with potential for future combination therapies.

Read the full abstract

All mentions

Decitabine Monotherapy in Acute Myeloid Leukemia Treatment Outcomes

Decitabine is a hypomethylating agent used for AML patients unfit for chemotherapy, improving survival and response rates based on clinical trials. It is well tolerated across age groups and effective in various AML…

AJE Video Bytes · Jun 15, 2023 210 views

Advances in Therapy

@AdvancesTherapy · X

Decitabine Monotherapy in Patients with Acute Myeloid Leukemia: Authors add a #videoabstract and #graphicalabstract to their publication. View these features and the full article here: https://t.co/LYU6dDfww9 #AML #leukemia https://t.co/XIv6myib8u

Jul 31, 2023 · 1,192 followers View post →

BIOMEDICAL RESEARCH

@RBiogical · X

Apr 5, 2022 · 2 likes · 996 followers View post →

Laith

@our_science · X

RT @AlbertP33498937: The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia https://t.co/NrMORAvQ5W #Acutemye…

Mar 18, 2022 · 1 share · 3,889 followers View post →

Scientific Papers

@AlbertP33498937 · X

Mar 18, 2022 · 3 likes · 1 share · 573 followers View post →

Keith Stockerl-Goldstein, MD

@CyclingDoctor · X

RT @PaperbirdsM: New article: Correction to: The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia https://t…

Feb 16, 2022 · 1 share · 2,509 followers View post →

Paperbirds_Hematology

@PaperbirdsM · X

New article: Correction to: The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia https://t.co/nFz6pp1HgO #AML #leusm #hematology https://t.co/sAikO6Cc6z

Feb 16, 2022 · 1 share · 912 followers View post →

Research feeds

@FeedsResearch · X

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia https://t.co/HaFulocv0k #Acutemyeloidleukemia; #decitabine; #Elderly; #Hypomethylatingagents; #HMAs

Feb 12, 2022 · 8 likes · 2 shares · 1,320 followers View post →

Research Updates

@researchupdate7 · X

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia https://t.co/1qFvKLzTEC #Acutemyeloidleukemia; #decitabine; #Elderly; #Hypomethylatingagents; #HMAs

Feb 11, 2022 · 2 likes · 540 followers View post →

Paperbirds_Hematology

@PaperbirdsM · X

New article: The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia https://t.co/OsZp6ABRZf #AML #leusm #hematology https://t.co/HtsukPAnnQ

Nov 17, 2021 · 1 like · 912 followers View post →

Advances in Therapy

@AdvancesTherapy · X

This Newly Published #OpenAccess Review Discusses the Clinical Value of #Decitabine Monotherapy in Patients With Acute Myeloid #Leukemia https://t.co/LYU6dDfww9 #AML #oncology https://t.co/lHTeDFh8wZ

Nov 17, 2021 · 1,192 followers View post →

John Charles Rotondo, PhD

@JC_Rotondo · X

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia https://t.co/2nt5dUgqQB #Acutemyeloidleukemia; #decitabine; #Elderly; #Hypomethylatingagents; #HMAs

Nov 17, 2021 · 7 likes · 1 share · 1,826 followers View post →